Early initiation of treatment with intramuscular (IM) interferon (IFN) Î²-1a in patients with a single demyelinating event suggestive of multiple sclerosis (MS) has been shown to reduce the risk of a second event. This study investigated the characteristics of patients with clinically isolated syndrome (CIS), conversion to clinically definite MS and quality of life (QoL) in clinical practice. The better understanding of early phases of the disease prompted studies to investigate whether early interventions could delay the onset of clinically definite MS. For example, in the CHAMPS pivotal study, the effect of intramuscular (IM) interferon (IFN) Î²-1a on conversion to clinically definite MS in individuals with a first demyelinating event was compared to placebo. Over the last decade, there has been a shift towards earlier treatment in patients considered at risk developing clinically definite MS after a first demyelinating event suggestive of MS (that is, with lesions apparent in brain MRI). In addition to the CHAMPIONS study with IM IFNÎ²-1a mentioned earlier.
Last date updated on January, 2021